The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved. We conducted a prospective, multicentered, phase II trial. A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors. The primary study end point was non-relapse mortality (NRM). Histologies were nonHodgkin's lymphomas (NHL) (indolent (LG-NHL), n ¼ 63; aggressive (HG-NHL), n ¼ 61; mantle cell lymphoma (MCL), n ¼ 14) and Hodgkin's disease (HD, n ¼ 32). Median follow-up was 33 months (range, 12-82). The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P ¼ 0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (Po0.001). Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P ¼ 0.04). Molecular remission occurred in 94 and 40% (P ¼ 0.002) of patients with FL and CLL, respectively. On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR) ¼ 3.6), diagnosis of HD (HR ¼ 3.5), and acute GVHD (HR ¼ 5.9). RIC allogeneic SCT is a feasible and effective salvage strategy in both indolent and aggressive NHL
Introduction
Over the last decade, expanding treatment strategies have improved survival of patients affected by lymphoid malignancies. However, those who relapse after second-line chemotherapy or autologous transplantation have a dismal prognosis and very few options for effective salvage treatment.
1,2 Myeloablative allogeneic stem cell transplantation (SCT) is potentially curative for recurrent indolent, aggressive, non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). The advantages rely on the use of a tumor-free graft and a postulated immunemediated graft-versus-lymphoma (GVL) effect. 3 Indirect evidence supporting the existence of the GVL effect derives from observation of clinical responses to immune modulatory maneuvers such as withdrawal of cyclosporine or use of donor lymphocyte infusions (DLIs). Several studies have indicated that relapse rates after allogeneic SCT were lower than after autologous SCT but that the higher non-relapse mortality (NRM) (25-50%) associated with allografting offset any survival benefit. [4] [5] [6] In 1997, minimal or reduced-intensity conditioning (RIC) regimens were introduced to reduce the organ toxicity of highdose myeloablative chemo/radiotherapy. They showed an efficient donor cell engraftment allowing in some cases the development of an immune graft-versus-malignancy effect. Analyses were mainly based on small cohorts or were retrospective and suggested that RIC regimens were associated with a lower NRM, even in patients heavily pretreated or affected by comorbidities. 7, 8 Promising results were found in indolent lymphomas, but quite controversial data have been reported in aggressive histotypes. 9, 10 Our study was designed in the year 2000 with the goal of investigating prospectively the practical role of RIC allogeneic SCT in several histotypes of relapsed/ refractory lymphomas, having in mind both the toxicity and efficacy of such a salvage procedure. Inclusion criteria targeted patients for whom this was basically the last option for cure. In addition, molecular monitoring of bone marrow minimal residual disease (MRD) was performed in patients attaining clinical remission.
Patients and methods

Patient characteristics
One hundred and seventy patients with relapsed/refractory NHL or HD received an allogeneic SCT from an HLA-identical or one antigen-mismatched sibling donor. A total of 44 of the 170 patients were updated in terms of clinical and molecular followup from two previously published studies in which patients followed the same treatment plan. 11, 12 A group of 126 patients were enrolled in a prospective phase II trial that started in March 2001 with a closing date for analysis of September 2006. Patient data were pooled and analyzed together. Inclusion criteria were as follows: (1) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) relapsing after at least two lines of conventional chemotherapy or within 1 year after a purine analogue-based regimen or after high-dose chemotherapy; (2) follicular lymphomas (FL) relapsing after two lines of conventional or high-dose chemotherapy; (3) mantle cell lymphomas (MCL) relapsing after conventional or high-dose chemotherapy; (4) diffuse large B-cell lymphomas (DLBCL) or transformed FL relapsing after two lines of conventional chemotherapy or highdose chemotherapy; (5) HD relapsed after autologous transplantation; (6) relapsed T-cell lymphomas; (7) refractory disease for all histologies; (8) age X45 and o70 years, and age below 45 years was allowed in cases of comorbidities (cardiac ejection fraction o45%; carbon monoxide diffusion capacity o50%; abnormal liver function or positive hepatitis tests) or heavy pretreatment (previously failed autologous transplant).
Approval was obtained from the Ethics Committee, and all patients gave their written informed consent. Patient and disease characteristics are summarized in Table 1 . Median age was 51 years (range, 20-69). Sixty-three patients had indolent lymphomas (LG-NHL) (FL, n ¼ 27; CLL/SLL, n ¼ 32; lymphoplasmacytoid, n ¼ 2; mucosa-associated lymphoid tissue lymphoma, n ¼ 2), 61 had aggressive lymphomas (HG-NHL) (DLBCL, n ¼ 31; peripheral T-cell lymphomas (PTCL) n ¼ 21, and lymphoblastic n ¼ 2; transformed LG-NHL n ¼ 7); 32 had HD; and 14 had MCL. Only 43 patients (25%) were in complete remission (CR) before transplantation.
Conditioning regimen, stem cell collection and DLI All patients received a RIC regimen consisting of thiotepa (10 mg/kg), cyclophosphamide (60 mg/kg) and fludarabine (60 mg/ms) followed by transplantation on day 0.
12 Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood hematopoietic stem cells (PBSC) were used for 138 patients (81%) and marrow cells for 32 patients (19%). Median CD34 þ cell doses were 5.8 Â 10 6 and 3 Â 10 6 /kg for peripheral blood and marrow, respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A (CSA), adjusted to maintain blood levels of 200-300 ng/ml, and a short course of methotrexate (10 mg/ms day þ 1, 8 mg/ms days þ 3 and þ 6). Three patients with one mismatched antigen also received 7.5 mg/ms alemtuzumab on day À1. CSA was administered at the full dose through day þ 100 and, if GVHD did not occur, the dose was tapered by 10% every week thereafter.
Acute GVHD was classified according to Glucksberg et al. 13 criteria, and chronic GVHD was classified as limited or extensive following the Shulman et al. 14 criteria. All engrafting patients were considered evaluable for acute GVHD while 158 patients (93%) surviving more than 100 days were considered evaluable for chronic GVHD.
Lenogastrim at 5 mg/kg per day was administered subcutaneously from day þ 7 until the neutrophil count was at least 1000/ml for 3 consecutive days.
Patients showing signs of progressive disease or relapse received rapidly tapered CSA and were considered eligible for DLIs. An escalated regimen was used for most patients, starting with 1 Â 10 6 /kg CD3 þ cells with a dose escalation every 6 weeks in the absence of GVHD.
Disease evaluation and molecular monitoring
Clinical response was evaluated according to the criteria reported by Cheson et al. 15 Chimerism in peripheral blood was assessed as described previously. 12 MRD was monitored in FL and CLL patients in CR after allogeneic SCT. Samples from diagnostic bone marrow aspirates were taken before and after SCT. Bcl-2 or immunoglobulin heavy chain gene rearrangements (IgH) were used as tumor markers. MRD was evaluated Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CR, complete remission; FL, follicular cell lymphomas; HD, Hodgkin's disease; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma. *These two patients had a diagnosis of HD.
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Study end points and statistical analysis
The primary end point was NRM. Sample size was calculated to obtain a reduction of NRM from 40 (historical data from the Italian bone marrow transplant registry (GITMO)) to 20% at 1 year. The secondary end points were: overall survival (OS), progression-free survival (PFS, defined as progression of the disease or death regardless of cause), incidence of relapse, incidence of acute and chronic GVHD and engraftment. Details about statistical analysis [17] [18] [19] [20] were given in the Supplementary Informations.
Results
Engraftment and chimerism
The median times to neutrophil (40.5 Â 10 9 /l) and platelet (420 Â 10 9 /l) recovery were 13 (range, 9-26) and 14 days (range, 9-107), respectively. There was a significant difference between PBSC and marrow recipients in terms of neutrophil recovery (median: 13 versus 16 days; P ¼ 0.006, KolmogorovSmirnov test) and in platelet recovery (median: 13 versus 16 days; P ¼ 0.006).
Chimerism studies were evaluated in 153 patients (90%) and were not performed in 17 patients (n ¼ 6 early death; n ¼ 11 not performed). In patients achieving full donor chimerism in the first 6 months after SCT, this analysis was no longer evaluated. In the first 20 patients, we evaluated lineage-specific chimerism (T and myeloid cells): the majority (90%) were full donor in both hematopoietic lineages. In the following patients (n ¼ 133), we assessed chimerism in peripheral blood only. Of the 133 patients tested at 1-3 months after transplantation, 109 (82%) had full donor hematopoiesis (495% donor cells) and 24 (18%) were mixed chimeras. On subsequent chimerism analysis at 6 months after allograft, 17 of 24 had converted to full donor chimerism. At final follow-up, four of seven patients with mixed chimerism at 6 months had evolved to full donor chimerism (only one after DLI), and three had died with mixed chimerism (n ¼ 2 disease, n ¼ 1 infection).
Non-relapse mortality
Twenty-two patients died of transplant-related causes between 1 and 23 months after transplantation. The most common cause of death was infection (n ¼ 12), which was concurrent to active GVHD in nine patients. Other causes were GVHD (five acute and two chronic), multiple organ failure (n ¼ 2), and an invasive diagnostic procedure (n ¼ 1).
The 100-day NRM cumulative incidence was 5% (95% CI, 3-10%). The NRM cumulative incidence was 11% (7-18%) and 14% (9-21%) at 1 and 3 years, respectively ( Figure 1 ). The low number of events prevented us from performing a reliable multivariate analysis of this end point. On univariate analysis, older age and acute GVHD were significantly associated with NRM ( Table 2 ). The 3-year NRM incidence was 14% (7-28%), 15% (8-27%), 32% (13-75%) and 3% (0.4-22%) for LG-NHL, HG-NHL, MCL and HD, respectively (P ¼ 0.091). (c and d) Cumulative incidence curves of relapse in different lymphoma subtypes according to disease status before allogeneic transplantation. The 3-year cumulative incidence of relapse was 32% for indolent, 24% for aggressive and 72% for HD in patients with chemosensitive disease who underwent transplantation. The 3-year cumulative incidence of relapse was 27% for indolent, 68% for aggressive and 91% for HD in patients with refractory disease who underwent transplantation. HD, Hodgkin's disease; NRM, non-relapse mortality; PFS, progression-free survival.
Graft-versus-host disease
All patients were evaluable for acute GVHD, which occurred in 59 patients (35%); 36 (21%) grade II and 23 (14%) grade III or IV. Of 158 patients evaluable for chronic GVHD, 43 (27%) developed the limited and 39 (25%) the extensive form. The overall 3-year chronic GVHD cumulative incidence was 49% (41-57%). Of note, chronic GVHD incidence was similar in patients receiving peripheral blood versus bone marrow cells: the 3-year cumulative incidence was 49% (41-59%) versus 44% (28-70%), respectively (P ¼ 0.794).
Lymphoma relapse
The disease relapsed or progressed in 62 (36%) patients, causing death in 32 of them. However, 16 of the 30 surviving patients (n ¼ 5 indolent, n ¼ 6 aggressive, n ¼ 3 HD and n ¼ 2 MCL) attained a clinical response after CSA withdrawal (n ¼ 4) or chemotherapy associated or not with DLIs (n ¼ 12). The median time to disease progression was 6 months after SCT (range, 1-42 months). The 1-and 3-year cumulative incidence of relapse was 31% (24-39%) and 40% (32-49%), respectively. The lymphoma subtype had a significant effect on relapse risk: the 3-year cumulative incidence of relapse was 29% (19-45%), 31% (20-47%), 35%(14-85%) and 81% (66-99%) for LG-NHL, HG-NHL, MCL and HD, respectively (Po0.001). A trend toward a higher incidence of relapse was observed in patients in partial remission or with refractory disease before allograft (at 3 years 38% (27-52%) and 50% (37-67%) versus 28% (15-50%) for patients in CR, P ¼ 0.057). Patients receiving a previous autograft had a higher incidence of relapse (P ¼ 0.030). At multivariate analysis, disease status before allograft (P ¼ 0.014) and lymphoma subtype (Po0.001) retained significance (data not shown). We also investigated the interaction between disease status before allograft and lymphoma subtype: HD and HG-NHL tended to have a worse prognosis when they underwent transplantation with refractory disease (Figure 1 ).
Survival
The median follow-up for the whole population was 33 months (12-82). At last follow-up, 116 patients were alive (n ¼ 93 CR, n ¼ 6 PR and n ¼ 17 PD), and 54 had died from any cause. The 3-year OS and PFS probability estimates were 62% (54-71%) and 46% (39-55%), respectively ( Figure 1) .
Disease status before transplantation and acute GVHD were significant for OS and PFS in both univariate and multivariate analysis (Tables 2 and 3 ). In particular, the 3-year OS probability was 46% for patients with refractory disease, 61% for patients in PR and 88% for patients in CR (P ¼ 0.002) (Table 2; Figure 2 ). Such differences in survival probabilities corresponded to an approximately 3.5-fold risk of death for patients with refractory disease, and a 2-fold risk of death for patients in PR as compared with patients in CR (Table 3) . Severe acute GVHD increased the risk of death by about six times and the risk of failure by three times. In addition, a previously failed autograft significantly doubled the risk of death.
The 3-year OS was 69% (56-83%) for LG-NHL, 69% (57-82%) for HG-NHL, 45% (24-86%) for MCL and 32% Abbreviations: CI, 95% confidence interval; CR, complete remission; GVHD, graft-versus-host disease; HD, Hodgkin's disease; MCL, mantle cell lymphoma; NRM, non-relapse mortality; OS, overall survival; PFS, progression-free survival; PR, partial remission. The estimates are given in percentages at 3 years after transplantation. *P-value with log-rank test; **Values corresponding to the 25th and 75th percentiles of the age distribution.
w P-value with Gray test. As regards age, P-value is with the Wald test in a Fine and Gray model.
Allogeneic stem cell transplantation P Corradini et al (15-68%) for HD (P ¼ 0.058; Table 2 and Figure 2 ). The effect of lymphoma subtype was significant at multivariate analysis: HD patients had roughly a 3.5-and 4-fold risk of death or progression, respectively, as compared to patients with LG-NHL. The occurrence of a limited or extensive chronic GVHD was not statistically significant on multivariate analysis for both OS and PFS (Table 3) . However, when investigating the effect of chronic GVHD on OS across the different histotypes, we found that NHL had a better OS than HD (hazard ratio (HR) ¼ 0.73, P-value for interaction between GVHD and histotype: Po0.035), suggesting a more prominent GVL effect.
Outcome of specific subtypes
We further analyzed indolent (CLL/SLL and FL) and aggressive lymphomas (B and T cell) because of their potentially different susceptibilities to the immune-mediated GVL effect (Supplementary Table 1 ).
The above-mentioned subgroups were similar in terms of number of previous treatments or pre-transplant disease status. In patients affected by CLL/SLL, a detailed analysis of prognostic factors was required for subjects receiving fewer than two lines of chemotherapy (n ¼ 18); these factors were unmutated VH status (n ¼ 8), poor cytogenetic risk (n ¼ 2) and refractoriness to fludarabine (n ¼ 8).
Notably, we observed a significant difference in relapse risk (14% versus 46%, 3 years, P ¼ 0.040) and OS (88% versus 53%, 3 years, P ¼ 0.013) between patients affected by FL versus CLL/ SLL, respectively.
We did not observe a significant difference in relapse risk (24% versus 36%, 3 years, P ¼ 0.32), and OS (73% versus 62%, 3 years OS, P ¼ 0.596) between patients with aggressive lymphoma of B-or T-cell origin, respectively.
MRD evaluation in FL and CLL
CR was achieved in 47 patients: 31 (n ¼ 15 CLL, n ¼ 16 FL) had a molecular marker (Bcl-2, n ¼ 12 or IgH, n ¼ 19) and thus were monitored for MRD. The median molecular follow-up was 25 months (range, 6-69). The achievement of molecular remission was more frequent in FL (15 of 16) than CLL patients (6 of 15) (P ¼ 0.002). Molecular remission was more rapidly achieved in FL, with 81 and 94% of the patients being persistently negative at 6 and 25 months, respectively. Among CLL patients, only four patients were persistently negative and did not relapse. In contrast, four relapses were seen in the five patients with persistent PCR positivity. The remaining six patients revealed a mixed pattern: (i) delayed clearance of MRD occurred in two patients, 6 months after SCT; (ii) one relapsed; and (iii) three patients are still in clinical CR despite the mixed pattern of the molecular disease. Figure 3 shows the curves of cumulative incidence of relapse after 6 months from transplantation according to the molecular response during the first 6 months (landmark analysis). The 3-year cumulative incidence was 40% (19-83%) for PCR-positive or mixed and 0% for the PCRnegative patients (P ¼ 0.010). 
Response to DLI
A total of 33 of 170 patients (20%) received post-transplant DLI for a total of 56 infusions (median, 1; range, 1-4). The median time to first DLI was 240 days (range, 52-1825). Of 27 patients receiving DLIs for disease progression or relapse, 9 (33%) received chemotherapy before DLIs and therefore could not be appropriately evaluated for the GVL effect only. Seven of eighteen patients receiving DLIs alone showed evidence of disease response (Supplementary Table 2 ).
Discussion
In the present report, we show that allogeneic SCT is an effective and feasible salvage treatment for relapsed NHL. An NRM rate of 14% at 3 years is rather low and compares favorably with the majority of the studies investigating RIC regimens in hematological tumors. 9, 10, 21, 22 A low NRM is particularly encouraging given the fact that the patients were elderly and/or heavily pretreated.
As in myeloablative transplants, acute GVHD has been identified as an adverse prognostic factor for NRM: of the 22 patients dying of treatment-related complications in this study, 19 (86%) had concomitant acute GVHD. Of importance, most of our patients received PBSC, but the overall 3-year cumulative incidence of chronic GVHD was not increased (49%), with a limited incidence of extensive forms (25%). A possible explanation for this finding is that we designed the protocol based on the use of a fixed range of donor CD34 þ cells (4-8 Â 10 6 /kg). 23 In multivariate analysis, the lymphoma subtype and the disease status at transplantation were significantly associated with outcome. Aggressive NHL had a 3-year OS of 69%, and there was no difference between B-and T-cell histologies. This analysis further extends and corroborates our previous observation that allogeneic SCT may overcome the unfavorable prognostic impact of the T-cell phenotype. 11 Recently, two reports on myeloablative allogeneic SCT for aggressive lymphomas reported encouraging OS, but the results of RIC regimens seemed disappointing. 24, 25 A recent multicenter study 21 employing an alemtuzumab-containing RIC regimen included 37 patients with aggressive histology and reported an actuarial 3-year relapse rate and OS of 52 and 34%, respectively. Our more promising results can be explained by the absence of in vivo T-cell depletion and the limited number of patients with refractory disease (only 23%, who did have a high relapse rate, Figure 1 ). Our data suggest that with RIC regimens, the T-cell depletion should be avoided because it can decrease or abrogate the postulated GVL effect.
In agreement with others, 9,26 we had good results in the patients with LG-NHL, with a 3-year OS of 69%. However, despite the fact that pre-transplant clinical characteristics between FL and CLL were not significantly different, we detected a higher risk of relapse and fewer molecular remissions in CLL patients. CLL was generally considered a disease very susceptible to an immune-mediated effect, but this assumption is probably only partially true.
The differences, in terms of outcome, obtained by others groups in CLL [27] [28] [29] may be in part explained by the following considerations: (i) a different selection of patients as pretransplantation characteristics (40% of our patients had refractory disease and were heavily pretreated; (ii) the use of Rituximab after conditioning, as reported by Khouri et al., 27 might have improved the graft-versus-leukemia effect; (iii) a higher incidence of chronic GVHD in the studies of Schetelig et al. 28 and Sorror et al. 29 (probably due to the inclusion of recipients of unrelated grafts).
Of importance, in our study, patients achieving molecular remission did not relapse; thus, MRD eradication might become a very important therapeutic goal for long-term disease control (Figure 3 ).
Unfortunately, we had disappointing survival curves in HD patients (32% OS at 3 years). The cumulative incidence of relapse was relevant also in patients with sensitive relapse (Figure 1) , suggesting that the existence of a GVL effect in HD remains questionable. The more promising results suggested by the experience of Peggs et al. 30 (4-year OS and PFS of 56 and 39%, respectively) might be explained by the fact that they included patients with a late relapse after autologous SCT. In addition, the inclusion of alemtuzumab in the conditioning might have had an activity against cytokine-secreting lymph node accessory cells. reported a lower relapse rate in 33 patients with advanced MCL, but they also included recipients of unrelated SCT (50%), who are expected to exhibit a more prominent GVL effect.
In conclusion, we report from a prospective trial several clinically relevant findings: (1) a lower risk of death or progression for patients in CR versus those only in PR before SCT (thus, responding patients should be encouraged to continue salvage therapy for further cytoreduction until they possibly attain a CR; this is particularly relevant in aggressive lymphomas); (2) a low NRM mortality at 3 years; (3) no increase of extensive chronic GVHD using a fixed dose of CD 34 þ cells; (4) usefulness of molecular monitoring in predicting patients with a low relapse risk and (5) the implication that HD patients should be transplanted only in the context of a clinical trial.
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